1
|
Chaaban S, Istvan M, Schreck B, Laigo P, Rousselet M, Grall-Bronnec M, Pain S, Victorri-Vigneau C. Cannabis use and dependence among festival attendees: results from the French OCTOPUS survey. BMC Public Health 2024; 24:992. [PMID: 38594675 PMCID: PMC11003156 DOI: 10.1186/s12889-024-18496-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 04/01/2024] [Indexed: 04/11/2024] Open
Abstract
BACKGROUND Chronic use of cannabis is associated with an increased risk of psychosocial, mental and physical health impairments. Sociohealth institutions reach a very limited proportion of cannabis users in need of treatment. Using data collected from festival attendees, this study aimed to estimate the prevalence of dependent cannabis users and to characterize cannabis dependence. METHODS We used data from the cross-sectional OCTOPUS survey carried out at 13 music events in the French department of Loire-Atlantique between July 2017 and July 2018. 383 participants aged 18 or older underwent a face-to-face interview about their basic sociodemographics, tobacco use, alcohol use and past-year substance use. Using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, we estimated the prevalence of dependent cannabis users and characterized their dependence. RESULTS More than two-thirds of participants reported that they had used cannabis in the past 12 months. Among 194 regular cannabis users (at least monthly), 63.4% were dependent. At least 40% of regular users reported health and/or social consequences of cannabis use. Compared to nondependent cannabis users, dependent cannabis users were more likely to be stimulant users and hallucinogen users. CONCLUSIONS Dependent cannabis use is common among festival attendees, especially among stimulant or hallucinogen users. Festival settings may be important arenas for i) implementing efficient harm reduction measures to prevent dependence and ii) providing information on care structures and promoting the use of care to dependent users. In addition, healthcare professionals should be aware of trends in polysubstance use among dependent cannabis users.
Collapse
Affiliation(s)
- Sarah Chaaban
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Marion Istvan
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
| | - Benoit Schreck
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Pauline Laigo
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Morgane Rousselet
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France.
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France.
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France.
| | - Marie Grall-Bronnec
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Stéphanie Pain
- Centre d'addictovigilance, Service de Pharmacologie Clinique, CHU de Poitiers, 86000, Poitiers, France
- Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM U-1084, Université de Poitiers, 86000, Poitiers, France
| | - Caroline Victorri-Vigneau
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
| |
Collapse
|
2
|
Bouquet E, Blouin P, Pérault-Pochat MC, Carlier-Guérin C, Millot F, Ricco JB, De Keizer J, Pain S, Guétarni F. Maternal, Fetal and Neonatal Outcomes Related to Recreational Cannabis Use during Pregnancy: Analysis of a Real-World Clinical Data Warehouse between 2010 and 2019. Int J Environ Res Public Health 2023; 20:6686. [PMID: 37681826 PMCID: PMC10487904 DOI: 10.3390/ijerph20176686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 08/28/2023] [Accepted: 08/29/2023] [Indexed: 09/09/2023]
Abstract
BACKGROUND Cannabis is the main illicit psychoactive substance used in French childbearing women and very few data are available about adverse events (AEs) related to its use during pregnancy. The aim of this study was to evaluate the association between recreational cannabis use during pregnancy and adverse outcomes from a real-world clinical data warehouse. METHODS Data from the Poitiers University Hospital warehouse were analyzed between 1 January 2010 and 31 December 2019. Logistic regression models were used to evaluate associations between outcomes in three prenatal user groups: cannabis alone ± tobacco (C ± T) (n = 123), tobacco alone (T) (n = 191) and controls (CTRL) (n = 355). RESULTS Pregnant women in the C ± T group were younger (mean age: 25.5 ± 5.7 years), had lower pre-pregnancy body mass index (22.8 ± 5.5 kg/m2), more psychiatric history (17.5%) and were more likely to benefit from universal free health-care coverage (18.2%) than those in the T and CTRL groups. Cannabis use increases the occurrence of voluntary interruption of pregnancy, at least one AE during pregnancy, at least one neonatal AE, the composite adverse pregnancy outcome over 28, prematurity and small for gestational age. CONCLUSION Given the trivialization of recreational cannabis use during pregnancy, there is an urgent need to communicate on AEs of cannabis use during pregnancy.
Collapse
Affiliation(s)
- Emilie Bouquet
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, 86000 Poitiers, France
- French National Institute of Health and Medical Research (INSERM) U1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 9, 86073 Poitiers, France
- Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, University of Poitiers, 86000 Poitiers, France
| | - Pascal Blouin
- Department of Clinical Research and Innovation, Poitiers University Hospital, 86000 Poitiers, France
| | - Marie-Christine Pérault-Pochat
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, 86000 Poitiers, France
- French National Institute of Health and Medical Research (INSERM) U1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 9, 86073 Poitiers, France
- Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, University of Poitiers, 86000 Poitiers, France
| | - Caroline Carlier-Guérin
- Department of Obstetrics and Gynecology, Poitiers University Hospital, 86000 Poitiers, France
| | - Frédéric Millot
- Department of Pediatrics, Poitiers University Hospital, 86000 Poitiers, France
| | - Jean-Baptiste Ricco
- Department of Clinical Research and Innovation, Poitiers University Hospital, 86000 Poitiers, France
| | - Joe De Keizer
- Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, University of Poitiers, 86000 Poitiers, France
| | - Stéphanie Pain
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, 86000 Poitiers, France
- French National Institute of Health and Medical Research (INSERM) U1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 9, 86073 Poitiers, France
| | - Farid Guétarni
- Department of Clinical Research and Innovation, Poitiers University Hospital, 86000 Poitiers, France
| |
Collapse
|
3
|
Zammit G, Mayleben D, Fietze I, Pain S, Gimona A, Seboek Kinter D, Dauvilliers Y. Effects of daridorexant on total sleep time (TST) and sleep stage proportions in patients with insomnia disorder. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Fietze I, Bassetti C, Mayleben D, Gimona A, Pain S, Seboek Kinter D. Effects of daridorexant on sleep and daytime functioning in older patients with insomnia disorder. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Danoux L, Pain S, Andre-Frei V. 246 Inhibition of Cutibacterium acnes virulence to reduce oily skin imperfections. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Pain S, Brot S, Gaillard A. Neuroprotective Effects of Neuropeptide Y against Neurodegenerative Disease. Curr Neuropharmacol 2022; 20:1717-1725. [PMID: 34488599 PMCID: PMC9881060 DOI: 10.2174/1570159x19666210906120302] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 07/31/2021] [Accepted: 08/31/2021] [Indexed: 11/22/2022] Open
Abstract
Neuropeptide Y (NPY), a 36 amino acid peptide, is widely expressed in the mammalian brain. Changes in NPY levels in different brain regions and plasma have been described in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and Machado-Joseph disease. The changes in NPY levels may reflect the attempt to set up an endogenous neuroprotective mechanism to counteract the degenerative process. Accumulating evidence indicates that NPY can function as an anti-apoptotic, anti-inflammatory, and pro-phagocytic agent, which may be used effectively to halt or to slow down the progression of the disease. In this review, we will focus on the neuroprotective roles of NPY in several neuropathological conditions, with a particular focus on the anti-inflammatory properties of NPY.
Collapse
Affiliation(s)
- Stéphanie Pain
- Laboratoire de Neurosciences Expérimentales et Cliniques-LNEC INSERM U-1084, Université de Poitiers, LNEC,
F-86000 Poitiers, France; ,CHU Poitiers, Poitiers, F-86021, France
| | - Sébastien Brot
- Laboratoire de Neurosciences Expérimentales et Cliniques-LNEC INSERM U-1084, Université de Poitiers, LNEC,
F-86000 Poitiers, France;
| | - Afsaneh Gaillard
- Laboratoire de Neurosciences Expérimentales et Cliniques-LNEC INSERM U-1084, Université de Poitiers, LNEC,
F-86000 Poitiers, France; ,Address correspondence to this author at the Laboratoire de Neurosciences Expérimentales et Cliniques-LNEC INSERM U-1084, Université de Poitiers, LNEC, F-86000 Poitiers, France; E-mail:
| |
Collapse
|
7
|
Mahajan R, Adams A, Allmond J, Alvarez Pol H, Argo E, Ayyad Y, Bardayan D, Bazin D, Budner T, Chen A, Chipps K, Davids B, Dopfer J, Friedman M, Fynbo H, Grzywacz R, Jose J, Liang J, Pain S, Perez-Loureiro D, Pollacco E, Psaltis A, Ravishankar S, Rogers A, Schaedig L, Sun LJ, Surbrook J, Wheeler T, Weghorn L, Wrede C. Measuring the 15O( α, γ) 19Ne Reaction in Type I X-ray Bursts using the GADGET II TPC: Software. EPJ Web Conf 2022. [DOI: 10.1051/epjconf/202226011034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
15O(α,γ)19Ne is regarded as one of the most important thermonuclear reactions in type I X-ray bursts. For studying the properties of the key resonance in this reaction using β decay, the existing Proton Detector component of the Gaseous Detector with Germanium Tagging (GADGET) assembly is being upgraded to operate as a time projection chamber (TPC) at FRIB. This upgrade includes the associated hardware as well as software and this paper mainly focusses on the software upgrade. The full detector set up is simulated using the ATTPCROOTv 2 data analysis framework for 20Mg and 241Am.
Collapse
|
8
|
Wheeler T, Adams A, Allmond J, Alvarez Pol H, Argo E, Ayyad Y, Bardayan D, Bazin D, Budner T, Chen A, Chipps K, Davids B, Dopfer J, Friedman M, Fynbo H, Grzywacz R, Jose J, Liang J, Mahajan R, Pain S, Pérez-Loureiro D, Pollacco E, Psaltis A, Ravishankar S, Rogers A, Schaedig L, Sun LJ, Surbrook J, Weghorn L, Wrede C. Measuring the 15O(α, γ) 19Ne reaction in Type I X-ray bursts using the GADGET II TPC: Hardware. EPJ Web Conf 2022. [DOI: 10.1051/epjconf/202226011046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Sensitivity studies have shown that the 15O(α, γ)19Ne reaction is the most important reaction rate uncertainty affecting the shape of light curves from Type I X-ray bursts. This reaction is dominated by the 4.03 MeV resonance in 19Ne. Previous measurements by our group have shown that this state is populated in the decay sequence of 20Mg. A single 20Mg(βp α)15O event through the key 15O(α, γ)19Ne resonance yields a characteristic signature: the emission of a proton and alpha particle. To achieve the granularity necessary for the identification of this signature, we have upgraded the Proton Detector of the Gaseous Detector with Germanium Tagging (GADGET) into a time projection chamber to form the GADGET II detection system. GADGET II has been fully constructed, and is entering the testing phase.
Collapse
|
9
|
Cadau S, Gault M, Berthelemy N, Gauché D, Pons C, Leprince C, Andre-Frei V, Simon M, Pain S. 112 A new 3D skin model colonized with bacteria for a better understanding of Atopic Dermatitis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Bouquet E, Pain S, Eiden C, Jouanjus E, Richard N, Fauconneau B, Pérault-Pochat MC. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017). Br J Clin Pharmacol 2021; 87:3925-3937. [PMID: 34282851 DOI: 10.1111/bcp.14812] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 02/23/2021] [Accepted: 02/25/2021] [Indexed: 12/24/2022] Open
Abstract
AIMS To describe the adverse events (AEs) of recreational cannabis use in France between 2012 and 2017. METHODS AEs related to recreational cannabis use, alone or in combination with alcohol and/or tobacco reported to the French Addictovigilance Network were analysed (excluding cannabidiol and synthetic cannabinoids). RESULTS Reporting of AEs tripled between 2012 (n = 179, 6.3%, 95% confidence interval [CI] = 5.4-7.2) and 2017 (n = 562, 10.1%, 95% CI = 9.3-10.9), reaching 2217 cases. They concerned mainly men (76.4%) and users aged between 18 and 34 years (18-25: 30.9%; 26-34: 26.3%, range: 12-84 years). Cannabis was mainly inhaled (71.6%) and exposure was most often chronic (64.2%). Many types of AEs were reported: psychiatric (51.2%), neurological (15.6%), cardiac (7.8%) and gastrointestinal (7.7%), including unexpected AEs (n = 34, 1.1%). The most common effect was dependence, ranging from 10.1% (95% CI = 7.9-12.3) to 20.3% (95% CI = 17.3-23.2) over the study period. Cannabinoid hyperemesis syndrome (n = 87, 2.8%) emerged from 2015. Deaths accounted for 0.2% of all AEs (4 men and 3 women aged on average 35 years). A chronic pattern of cannabis use was reported in 4 of them (intracranial hypertension in the context of lung cancer, suicide, cerebral haematoma, neonatal death with concomitant chronic alcohol use), while in the other cases the toxicological analysis identified cannabis use (ruptured aneurysm and unknown aetiology). CONCLUSION This study showed a multitude of AEs related to recreational cannabis use, including unexpected AEs and deaths. It highlights the problem of dependence and the emergence of cannabinoid hyperemesis syndrome.
Collapse
Affiliation(s)
- Emilie Bouquet
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, France
| | - Stéphanie Pain
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, France.,INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France
| | - Céline Eiden
- Addictovigilance Center, Montpellier University Hospital, France
| | - Emilie Jouanjus
- Addictovigilance Center, Toulouse University Hospital, France
| | - Nathalie Richard
- French National Agency for Medicines and Health Products Safety (ANSM), Saint-Denis, France
| | - Bernard Fauconneau
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, France
| | - Marie-Christine Pérault-Pochat
- Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University Hospital, France.,INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France
| | | |
Collapse
|
11
|
Pain S, Fauconneau B, Ricou J, Pérault-Pochat MC. Changement de règlementation sur la codéine en 2017 en France : quelles conséquences pour les pharmaciens ? Therapie 2021. [DOI: 10.1016/j.therap.2021.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Bouquet E, Pain S, Fauconneau B, Lesbordes M, Frouin E, Silvain C, Pérault-Pochat MC. Cocaine-induced acute hepatitis: A diagnosis not to forget. Clin Res Hepatol Gastroenterol 2021; 45:101462. [PMID: 32586784 DOI: 10.1016/j.clinre.2020.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 05/15/2020] [Accepted: 05/26/2020] [Indexed: 02/04/2023]
Affiliation(s)
- Emilie Bouquet
- Department of Clinical Pharmacology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France.
| | - Stéphanie Pain
- Department of Clinical Pharmacology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France
| | - Bernard Fauconneau
- Department of Clinical Pharmacology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France
| | - Matthieu Lesbordes
- Department of Cardiology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France
| | - Eric Frouin
- Department of Pathology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France
| | - Christine Silvain
- Department of Hepato-Gastroenterology, Poitiers University Hospital, 2, rue de la Milétrie, 86021 Poitiers, France
| | | |
Collapse
|
13
|
Balayssac D, Pereira B, Cuq P, Douris J, Ferrari L, Boutet-Robinet E, Lechevrel M, Demeilliers C, Rat P, Coudoré F, Verron E, Lacarelle B, Guitton J, Courtois A, Allorge D, Pain S, Guerbet M, Collin A, Vennat B, Brousse G, Authier N, Laporte C. Perception of pharmacy students toward opioid-related disorders and roles of community pharmacists: A French nationwide cross-sectional study. Subst Abus 2020; 42:706-715. [PMID: 33320801 DOI: 10.1080/08897077.2020.1850607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Background: Community pharmacists are among the frontline health professionals who manage patients with an opioid-related disorder (ORD). Pharmacists frequently have a negative attitude toward these patients, which could have a negative impact on their management. However, education on ORD may improve the attitude of future healthcare professionals. This cross-sectional study aimed to assess French pharmacy students' perceptions of ORD. Methods: This online survey was performed by emails sent to French pharmacy schools (between January 14, 2019 and May 31, 2019). The primary outcome was the perception (visual analogic scale) of ORD as a disease, the roles of community pharmacies (delivery of opioid agonist therapy-OAT and harm reduction kits), and the efficacy of OAT. The secondary outcomes assessed professional experience, university experience of and education on ORD, and the individual characteristics of students. Results: Among the 1,994 students included, 76.3% perceived ORD as a disease and felt that it was normal for pharmacists to deliver OAT (78.9%) and harm reduction kits (74.6%). However, only 46.9% perceived OAT as being effective. Multivariable analyses showed that females had a more positive perception in recognizing ORD as a disease. The progression through university years increased the positive perception of ORD as a disease and the delivery of OAT and harm reduction kits by pharmacists. Education on substance-related disorders had no impact on any scores. Students who had already delivered OAT had a negative perception of their efficacy. The students who had already performed pharmacy jobs or traineeships had a negative perception of harm reduction kit delivery. Conclusion: Education on substance-related disorders had no impact on students' perceptions. It seemed that the maturity acquired through university years had a stronger impact on the students' perceptions of ORD. Efforts must be made to improve our teaching methods and reinforce the confidence of students in the roles of community pharmacists.
Collapse
Affiliation(s)
- David Balayssac
- Inserm U1107, NEURO-DOL, Université Clermont Auvergne, CHU Clermont-Ferrand, France
| | - Bruno Pereira
- Délégation à la recherche clinique et à l'innovation, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Pierre Cuq
- Faculté de Pharmacie, Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, ENSCM, Université de Montpellier, Montpellier, France
| | - Juliette Douris
- UFR de Pharmacie, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Luc Ferrari
- Institut Jean Lamour, UMR 7198 CNRS, Université de Lorraine, Nancy, France
| | - Elisa Boutet-Robinet
- Toxalim (Research Centre in Food Toxicology), INRAE, ENVT, INP-Purpan, UPS, Université de Toulouse, Toulouse, France
| | | | - Christine Demeilliers
- Environnement et Prédiction de la Santé des Populations, Laboratoire TIMC-IMAG (UMR-CNRS 5525), Université Grenoble-Alpes, La Tronche, France
| | - Patrice Rat
- Faculté de Pharmacie de Paris, CNRS UMR-8038 CiTCoM, Université de Paris, Paris, France
| | - François Coudoré
- Lab neuropharmacologie, CESP UMR-S1178, Université Paris-Saclay, Chatenay Malabry, Laboratoire de Microbiologie Clinique et Plateforme de dosage des anti-infectieux, Groupe Hospitalier Paris Saint Joseph, Paris, France
| | - Elise Verron
- UFR pharmacie, département E2M, CNRS 6230, Université de Nantes, Nantes, France
| | - Bruno Lacarelle
- SMARTc Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Assistance Publique des Hôpitaux de Marseille, Laboratoire de Pharmacocinétique et Toxicologie, Université Aix Marseille, Marseille, France
| | - Jérôme Guitton
- Laboratoire de Toxicologie, ISPBL, Faculté de Pharmacie de Lyon, Université Lyon 1, Lyon, France
| | - Arnaud Courtois
- CHU de Bordeaux, Centre Antipoison et de Toxicovigilance de Nouvelle Aquitaine, Université de Bordeaux, Bordeaux, France
| | - Delphine Allorge
- CHU Lille, Institut Pasteur de Lille, ULR 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Université de Lille, Lille, France
| | - Stéphanie Pain
- Laboratoire de Neurosciences Expérimentales et Cliniques - LNEC, INSERM U-1084, CHU Poitiers, Centre d'Addictovigilance, Pharmacologie clinique et vigilances, Université de Poitiers, Poitiers, France
| | - Michel Guerbet
- UNIROUEN, UNICAEN, ABTE, Normandie University, Rouen, France
| | - Aurore Collin
- Inserm U1107, NEURO-DOL, Université Clermont Auvergne, CHU Clermont-Ferrand, France
| | - Brigitte Vennat
- ACCePPT, UFR de Pharmacie, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Georges Brousse
- EA7280, UFR de Médicine, CHU Clermont-Ferrand Service de Psychiatrie B et d'addictologie, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Nicolas Authier
- Inserm U1107, NEURO-DOL, Université Clermont Auvergne, CHU Clermont-Ferrand, France
| | - Catherine Laporte
- Département de Médecine Générale, EA7280, UFR de Médicine, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
14
|
Zammit G, Seboek Kinter D, Bassetti C, Leger D, Hermann V, Pain S, Roth T. 0521 Daridorexant (ACT-541468), A Dual Orexin Receptor Antagonist for the Treatment of Insomnia Disorder: Double Blind, Randomized, Phase 3 Studies for Efficacy and Safety in Adult and Elderly Patients. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Daridorexant, a potent and selective orally administered dual orexin receptor antagonist (DORA), has shown dose-dependent efficacy and is well tolerated with minimal residual next-morning effects in two phase 2 studies in adult and elderly subjects with insomnia disorder. Following the favorable phase 2 results, clinical development was pursued with two pivotal phase 3 multi-center, double-blind, randomized, placebo-controlled studies to further assess efficacy and safety in adult and elderly subjects with insomnia disorder. Long-term safety and tolerability are being further evaluated in a double-blind placebo-controlled extension study.
Methods
Each of the pivotal studies include ~900 patients (~40% ≥65y), randomized 1:1:1 to one of two daridorexant arms or placebo. The studies differ in dose only (10 or 25 mg [NCT03545191], 25 or 50 mg [NCT03575104]). Both report objective primary outcomes at 1 and 3 months based on PSG (WASO and LSP). Secondary endpoints include self-reported nighttime benefit with Total Sleep Time (sTST), and daytime benefit using the validated Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). The patients undergo screening (7-13 d) and run-in (7-18 d) periods establishing eligibility and baseline, a 3-month double-blind treatment period, followed by a placebo run-out (7 d) to evaluate rebound insomnia and withdrawal effects and a 30-day safety follow-up. Additionally, subjects completing treatment could enroll in the 40-week double-blinded placebo-controlled extension trial [NCT03679884] to assess long-term safety.
Results
Enrollment in NCT03575104 (25/50 mg) was successfully completed and involves 76 sites across 10 countries; expected completion March 2020. Recruitment to study NCT03545191 (10/25 mg) is advanced; completion expected June 2020.
Conclusion
The comprehensive daridorexant phase 3 program includes 3 dose levels and replication of objective and subjective measurements at 1 and 3 months, while assessing self-reported nighttime benefit, and benefit during the day with a validated PRO instrument, as well as safety in insomnia disorder.
Support
Medical writing Randall Watson, (Idorsia). These studies were sponsored by Idorsia Pharmaceuticals Ltd.
Collapse
Affiliation(s)
| | | | - C Bassetti
- Inselspital Universitatsklinik für Neurologie, Bern, SWITZERLAND
| | - D Leger
- Universite Paris Descartes AP-HP, Paris, FRANCE
| | - V Hermann
- Idorsia Pharmeceuticals Ltd., Allschwil, SWITZERLAND
| | - S Pain
- Idorsia Pharmeceuticals Ltd., Allschwil, SWITZERLAND
| | - T Roth
- Division of Sleep Medicine and Research Center, Henry Ford Health System, Detroit, MI
| |
Collapse
|
15
|
Pain S, Deguil J, Belin J, Barraud P, Ragot S, Houeto JL. Regulation of Protein Synthesis and Apoptosis in Lymphocytes of Parkinson Patients: The Effect of Dopaminergic Treatment. NEURODEGENER DIS 2020; 19:178-183. [PMID: 32146463 DOI: 10.1159/000505750] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 12/31/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Parkinson disease (PD) is a neurodegenerative disorder characterized by progressive degeneration of the dopaminergic neurons in the substantia nigra, presumably due to increased apoptosis. In previous studies, we showed altered expression of proteins involved in mammalian target of rapamycin (mTOR) antiapoptotic and double-stranded RNA-dependent protein kinase (PKR) apoptotic pathways of translational control in experimental cellular and animal models of PD. RESULTS In this work, our results showed clear modifications in the expression of kinases involved in mTOR and PKR apoptosis pathways, in lymphocytes of PD patients treated or not with anti-PD treatment (levodopa), which confirmed the role played by apoptosis in the pathogenesis of this disease and the positive effect of treatment with medication on this parameter. Others proteins involved in apo-ptosis were also evaluated in lymphocytes of patients as the expression of the peripheral benzodiazepine receptor and caspase-3. CONCLUSION Translational control is altered in PD and hence its evaluation in peripheral blood mononuclear cells may serve as an early marker of apoptosis and indicate the efficacy of the dopaminergic treatment.
Collapse
Affiliation(s)
- Stéphanie Pain
- INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC, Université de Poitiers, Poitiers, France, .,Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France,
| | - Julie Deguil
- Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France
| | - Jeremie Belin
- Centre Expert Parkinson, Service de Neurologie, CHU de Tours, Tours, France
| | - Pauline Barraud
- Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France
| | - Stéphanie Ragot
- Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.,INSERM, CIC 1402, Poitiers, France
| | - Jean-Luc Houeto
- Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.,Service de Neurologie, CHU Poitiers, Poitiers, France.,INSERM, CIC 1402, Poitiers, France
| |
Collapse
|
16
|
Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Kinter DS, Pain S, Hedner J. Daridorexant (Act-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder: a randomized, double-blind, placebo-controlled, active-reference phase 2 study. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Pain S, Mine S, Jeanmaire C, André-Frei V. 558 Negative effect of blue light and potential impacts on the dermis. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Leoty-okombi S, Moussou P, André-Frei V, Pain S. 209 Study of skin microbiota impaired by skin hygiene habits. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Bardey V, Reymermier C, Pain S. 531 Epigenetic mechanism linked to pigmented spots explored by in silico, in vitro and in vivo methods. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Pain S, Fauconneau B, Bouquet E, Vasse-Terrier L, Pérault-Pochat MC. Severe craving associated with kaolin consumption. Eat Weight Disord 2019; 24:379-381. [PMID: 30255289 DOI: 10.1007/s40519-018-0583-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Accepted: 09/17/2018] [Indexed: 10/28/2022] Open
Abstract
PURPOSE Kaolin eating is an ancestral and worldwide tradition, particularly in women in order to relieve nauseas and abdominal troubles. Nevertheless, damaging effects such as anemia and intestinal troubles are well documented. However, compulsive disorders associated with kaolin intake are less known. RESULT We reported in this paper a severe craving observed in a young woman consuming kaolin for several years, associated with a microcytic iron-deficiency non-regenerative anemia. CONCLUSION This paper allows to draw attention among physicians who are rarely informed of this practice imported from abroad and have consequently a limited role in informing patients of the potential deleterious side effects of geophagia.
Collapse
Affiliation(s)
- Stéphanie Pain
- Department of Clinical Pharmacology, University Hospital of Poitiers, 2 rue de la Milétrie, BP 577, 86021, Poitiers Cedex, France.,Inserm U1084, University of Poitiers, 1, rue Georges Bonnet, 86022, Poitiers Cedex, France
| | - Bernard Fauconneau
- Department of Clinical Pharmacology, University Hospital of Poitiers, 2 rue de la Milétrie, BP 577, 86021, Poitiers Cedex, France.
| | - Emilie Bouquet
- Department of Clinical Pharmacology, University Hospital of Poitiers, 2 rue de la Milétrie, BP 577, 86021, Poitiers Cedex, France
| | | | - Marie-Christine Pérault-Pochat
- Department of Clinical Pharmacology, University Hospital of Poitiers, 2 rue de la Milétrie, BP 577, 86021, Poitiers Cedex, France.,Inserm U1084, University of Poitiers, 1, rue Georges Bonnet, 86022, Poitiers Cedex, France
| |
Collapse
|
21
|
Pain S, Vergote J, Gulhan Z, Bodard S, Chalon S, Gaillard A. Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y. Fundam Clin Pharmacol 2019; 33:544-548. [PMID: 30866091 DOI: 10.1111/fcp.12464] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 02/26/2019] [Accepted: 03/08/2019] [Indexed: 01/27/2023]
Abstract
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the nigro-striatal pathway. Interestingly, it has already been shown that an intracerebral administration of neuropeptide Y (NPY) decreases the neurodegeneration induced by 6-hydroxydopamine (6-OHDA) in rodents and prevents loss of dopamine (DA) and DA transporter density. The etiology of idiopathic PD now suggest that chronic production of inflammatory mediators by activated microglial cells mediates the majority of DA-neuronal tissue destruction. In an animal experimental model of PD, the present study shows that NPY inhibited the activation of microglia evaluated by the binding of the translocator protein (TSPO) ligand [3H]PK11195 in striatum and substantia nigra of 6-OHDA rats. These results suggest a potential role for inflammation in the pathophysiology of the disease and a potential treatment by NPY in PD.
Collapse
Affiliation(s)
- Stéphanie Pain
- Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC)-INSERM U1084, Pôle Biologie-Santé, Université de Poitiers, Poitiers, France
| | - Jackie Vergote
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Zuhal Gulhan
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Sylvie Bodard
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Sylvie Chalon
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Afsaneh Gaillard
- Laboratoire de Neurosciences Expérimentales et Cliniques (LNEC)-INSERM U1084, Pôle Biologie-Santé, Université de Poitiers, Poitiers, France
| |
Collapse
|
22
|
Pain S, Bouquet E, Fauconneau B, Brunet B, Guenezan J, Pérault-Pochat MC. Intoxications aiguës avec de la « china white » : les dangers des fentanyloïdes. Therapie 2018. [DOI: 10.1016/j.therap.2018.09.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Bouquet E, Pain S, Fauconneau B, Lesbordes M, Levillain P, Silvain C, Pérault-Pochat MC. Hépatite aiguë chez un consommateur régulier de cocaïne par voie inhalée : à propos d’un cas. Therapie 2018. [DOI: 10.1016/j.therap.2018.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Perri-Plandé J, Deschamps M, Baumevieille M, Gérardin M, Pizzoglio V, Fouilhe Sam-Lai N, Pochard L, Fabre F, Pain S, Batisse A, Serre A, Fournier-Choma C, Le Boisselier R, Caous AS, Kahn JP, Miremont-Salamé G, Daveluy A. Antalgiques stupéfiants ordonnances sécurisées (ASOS): évolution des prescriptions des antalgiques opioïdes en fonction des indications (2007–2017). Therapie 2018. [DOI: 10.1016/j.therap.2018.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Pain S, Batisse A, Ingrand I, Fauconneau B, Pérault-Pochat MC. Consumption of hallucinogenic plants and mushrooms by university students in France: A pilot study. Presse Med 2018; 47:1023-1025. [PMID: 30343825 DOI: 10.1016/j.lpm.2018.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 09/05/2018] [Accepted: 09/17/2018] [Indexed: 01/02/2023] Open
Affiliation(s)
- Stéphanie Pain
- CHU, CEIP-A de Poitiers, Ancien Pavillon Administratif, service de pharmacologie clinique et vigilances, rue de la Milétrie, BP 577, 86021 Poitiers cedex, France; UFR médecine-pharmacie, 6 rue de la Milétrie Bât D1, TSA 51115, 86073 Poitiers cedex 9, France; Laboratoire de neurosciences expérimentales et cliniques LNEC, Inserm U1084, Pôle Biologie Santé, bâtiment B36, 1, rue Georges Bonnet, BP 633 TSA 51106, 86073 Poitiers cedex 9, France.
| | - Anne Batisse
- Hôpital Fernard Widal, CEIP-A de Paris, 200, rue du Faubourg Saint-Denis, 75010 Paris, France
| | - Isabelle Ingrand
- UFR médecine-pharmacie, 6 rue de la Milétrie Bât D1, TSA 51115, 86073 Poitiers cedex 9, France
| | - Bernard Fauconneau
- CHU, CEIP-A de Poitiers, Ancien Pavillon Administratif, service de pharmacologie clinique et vigilances, rue de la Milétrie, BP 577, 86021 Poitiers cedex, France; UFR médecine-pharmacie, 6 rue de la Milétrie Bât D1, TSA 51115, 86073 Poitiers cedex 9, France
| | - Marie-Christine Pérault-Pochat
- CHU, CEIP-A de Poitiers, Ancien Pavillon Administratif, service de pharmacologie clinique et vigilances, rue de la Milétrie, BP 577, 86021 Poitiers cedex, France; UFR médecine-pharmacie, 6 rue de la Milétrie Bât D1, TSA 51115, 86073 Poitiers cedex 9, France; Laboratoire de neurosciences expérimentales et cliniques LNEC, Inserm U1084, Pôle Biologie Santé, bâtiment B36, 1, rue Georges Bonnet, BP 633 TSA 51106, 86073 Poitiers cedex 9, France
| |
Collapse
|
26
|
Pinder S, Shaaban A, Deb R, Desai A, Gandhi A, Lee A, Pain S, Wilkinson L, Sharma N. NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). Clin Radiol 2018; 73:682-692. [DOI: 10.1016/j.crad.2018.04.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 04/11/2018] [Indexed: 10/28/2022]
|
27
|
Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, Jouanjus É, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J. Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d’addictovigilance. Therapie 2017; 72:491-501. [DOI: 10.1016/j.therap.2017.01.010] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 01/16/2017] [Accepted: 02/14/2017] [Indexed: 11/30/2022]
|
28
|
Pain S, Chavant F, Fauconneau B, Guenezan J, Marjanovic N, Lardeur JY, Brunet B, Perault-Pochat MC. Dangerous intoxication after oral ingestion of poppers (alkyl nitrites): Two case reports. Therapie 2016; 72:397-399. [PMID: 27919469 DOI: 10.1016/j.therap.2016.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 07/01/2016] [Accepted: 09/23/2016] [Indexed: 10/20/2022]
Affiliation(s)
- Stéphanie Pain
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France.
| | - François Chavant
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| | - Bernard Fauconneau
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| | - Jérémy Guenezan
- Service urgences-SAMU-SMUR, CHU de Poitiers, 86021 Poitiers, France
| | | | | | - Bertrand Brunet
- Service de toxicologie et pharmacocinétique, CHU de Poitiers, 86021 Poitiers, France
| | - Marie-Christine Perault-Pochat
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| |
Collapse
|
29
|
Pain S, Bardey V, André-Frei V, Moulin L, Debret R. 172 DNA methylation targeting to rescue chronological and pathological loss of skin elasticity. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Rival D, Pain S, Chavan M, Cadau S, Gauché D, Fargier G, Moussou P, André-Frei V. 685 Study of functional fibrillary collagen network from the cell level to the matrix maturation. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 2015; 112:650-9. [PMID: 25625276 PMCID: PMC4333497 DOI: 10.1038/bjc.2014.653] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Revised: 11/04/2014] [Accepted: 12/04/2014] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). Secondary objectives included characterisation of the safety profile, pharmacokinetics (PKs) and pharmacodynamics (PDs). METHODS Heat-shock protein 990 was administered orally once or two times weekly on a 28-day cycle schedule in patients with advanced solid tumours. Dose escalation was guided by a Bayesian logistic regression model with overdose control. RESULTS A total of 64 patients were enrolled. Fifty-three patients received HSP990 once weekly at 2.5, 5, 10, 20, 30, 50 or 60 mg, whereas 11 patients received HSP990 two times weekly at 25 mg. Median duration of exposure was 8 weeks (range 1-116 weeks) and 12 patients remained on treatment for >16 weeks. Dose-limiting toxicities occurred in seven patients and included diarrhoea, QTc prolongation, ALT/AST elevations and central neurological toxicities. The most common drug-related adverse events were diarrhoea, fatigue and decreased appetite. Further dose escalation beyond 60 mg once weekly was not possible owing to neurological toxicity. Rapid absorption, no drug accumulation and large interpatient variability in PK exposures were observed. No objective responses were seen; 25 patients had a best overall response of stable disease. CONCLUSIONS Heat-shock protein 990 is relatively well tolerated, with neurological toxicity being the most relevant DLT. The single agent MTD/RP2D of HSP990 was declared at 50 mg once weekly.
Collapse
Affiliation(s)
- A Spreafico
- Drug Development Program, UHN – Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - J-P Delord
- Institut Claudius Regaud, Toulouse, France
| | - L De Mattos-Arruda
- Vall d'Hebron University Hospital, Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Y Berge
- Institut Claudius Regaud, Toulouse, France
| | - J Rodon
- Vall d'Hebron University Hospital, Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain
| | - E Cottura
- Institut Claudius Regaud, Toulouse, France
| | - P L Bedard
- Drug Development Program, UHN – Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - M Akimov
- Novartis Pharma AG, Basel, Switzerland
| | - H Lu
- Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
| | - S Pain
- Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
| | - A Kaag
- Novartis Pharma AG, Basel, Switzerland
| | - L L Siu
- Drug Development Program, UHN – Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - J Cortes
- Vall d'Hebron University Hospital, Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain
| |
Collapse
|
32
|
Pilgrim S, Pain S. Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers. Eur J Surg Oncol 2014; 40:670-2. [PMID: 24612652 DOI: 10.1016/j.ejso.2014.02.218] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Accepted: 02/06/2014] [Indexed: 11/28/2022] Open
Affiliation(s)
- S Pilgrim
- Department of General Surgery, Norfolk & Norwich University Hospital, Colney Lane, Norwich, United Kingdom.
| | - S Pain
- Department of General Surgery, Norfolk & Norwich University Hospital, Colney Lane, Norwich, United Kingdom
| |
Collapse
|
33
|
Pain S, Richard G, Chavant F, Remaudière B, Lardeur JY, Fauconneau B, Brunnet B, Mura P, Perault-Pochat MC. Intoxication volontaire aiguë à la trimébutine (Débridat®) : à propos d’un cas avec symptomatologie neurologique type morphinique. Therapie 2013; 68:405-7. [DOI: 10.2515/therapie/2013062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Accepted: 07/16/2013] [Indexed: 11/20/2022]
|
34
|
Decressac M, Pain S, Chabeauti PY, Frangeul L, Thiriet N, Herzog H, Vergote J, Chalon S, Jaber M, Gaillard A. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol Aging 2011; 33:2125-37. [PMID: 21816512 DOI: 10.1016/j.neurobiolaging.2011.06.018] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Revised: 06/10/2011] [Accepted: 06/18/2011] [Indexed: 11/26/2022]
Abstract
This study was aimed to investigate the potential neuroprotective effect of neuropeptide Y (NPY) on the survival of dopaminergic cells in both in vitro and in animal models of Parkinson's disease (PD). NPY protected human SH-SY5Y dopaminergic neuroblastoma cells from 6-hydroxydopamine-induced toxicity. In rat and mice models of PD, striatal injection of NPY preserved the nigrostriatal dopamine pathway from degeneration as evidenced by quantification of (1) tyrosine hydroxylase (TH)-positive cells in the substantia nigra pars compacta, levels of (2) striatal tyrosine hydroxylase and dopamine transporter, (3) dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) as well as (4) rotational behavior. NPY had no neuroprotective effects in mice treated with Y(2) receptor antagonist or in transgenic mice deficient for Y(2) receptor suggesting that NPY effects are mediated through this receptor. Stimulation of Y(2) receptor by NPY triggered the activation of both the ERK1/2 and Akt pathways but did not modify levels of brain derived neurotrophic factor (BDNF) or glial cell line-derived neurotrophic factor. These results open new perspectives in neuroprotective therapies using NPY and suggest potential beneficial effects in PD.
Collapse
Affiliation(s)
- Mickael Decressac
- Institut de Physiologie et Biologie Cellulaires, Université de Poitiers, Centre National de la Recherche Scientifique (CNRS), Poitiers, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Pain S, Altobelli C, Boher A, Cittadini L, Favre-Mercuret M, Gaillard C, Sohm B, Vogelgesang B, André-Frei V. Surface rejuvenating effect of Achillea millefolium extract. Int J Cosmet Sci 2011; 33:535-42. [PMID: 21711463 DOI: 10.1111/j.1468-2494.2011.00667.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Proopiomelanocortin is a precursor peptide that gives rise to several neuropeptides including adrenocorticotrophic hormone (ACTH) and β-endorphin. POMC-derived peptides have been shown to be synthesized in human epidermis where they modulate numerous skin functions. Because we previously observed that melanocortin receptor-2 and μ-opioid receptor 1, the respective receptors for ACTH and β-endorphin decreased with ageing in human epidermis, we have selected an active ingredient (INCI name: Achillea millefolium extract) able to upregulate receptor expressions. The aim of the present work was first to evaluate the effect of A. millefolium extract on the expression pattern of various epidermal differentiation markers ex vivo in normal human skin biopsies using quantitative image analysis and second to evaluate its capacity to rejuvenate the appearance of skin surface in vivo. Results show an improved expression profile of cytokeratin 10, transglutaminase-1 and filaggrin in cultured skin biopsies as well as an increased epidermal thickness. In vivo, a 2-month treatment with A. millefolium extract at 2% significantly improved the appearance of wrinkles and pores compared with placebo. Results were also directionally better than those of glycolic acid that was chosen as reference resurfacing molecule.
Collapse
Affiliation(s)
- S Pain
- BASF Beauty Care Solutions France S.A.S, 32 rue Saint-Jean-de-Dieu, F-69366, Lyon Cedex 07, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Deguil J, Chavant F, Lafay-Chebassier C, Pérault-Pochat MC, Fauconneau B, Pain S. Time course of MPTP toxicity on translational control protein expression in mice brain. Toxicol Lett 2010; 196:51-5. [DOI: 10.1016/j.toxlet.2010.03.1121] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Revised: 03/26/2010] [Accepted: 03/30/2010] [Indexed: 01/03/2023]
|
37
|
Pain S, Dezutter C, Reymermier C, Vogelgesang B, Delay E, André V. Age-related changes in pro-opiomelanocortin (POMC) and related receptors in human epidermis. Int J Cosmet Sci 2010; 32:266-75. [PMID: 20384899 DOI: 10.1111/j.1468-2494.2009.00569.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
SYNOPSIS Much effort has been placed in cosmetic research for better understanding of the effects of ageing on skin's appearance, structure, mechanical properties and function. It is now of common knowledge that UV radiations induce pre-mature skin ageing notably in the epidermis where UV radiations induce keratinocyte differentiation. As UV radiations have also been shown to regulate the pro-opiomelanocortin (POMC) peptide family in the skin and because no study has been conducted so far to investigate the age-related changes in POMC and related receptors, we analysed POMC, MC-1R, MC-2R and MOR-1 at mRNA level and MC-1R, MC-2R and MOR-1 at protein level too in primary cultures of normal human keratinocytes obtained from female donors aged from 17 to 75 years old. Regarding the gene expressions, we observed that MC-1R, MC-2R and MOR-1 suffered a dramatic decrease after 50 years of age, whereas POMC increased five-fold. Western blot analysis confirmed these results except for MOR-1 whose expression appeared to decrease at older age, around 70 years old. Immunostainings specific to MC-1R, MC-2R and MOR-1 performed on full-thickness skin biopsies also revealed an intense staining in the basal and spinous layers of a 30-year-old donor, whereas no reactivity could be observed in a 60-year-old one. We conclude that POMC and POMC-related receptors suffer a dramatically disturbed balance with ageing and that this may be implicated in the general process of skin ageing.
Collapse
Affiliation(s)
- S Pain
- BASF Beauty Care Solutions, 32 rue Saint Jean de Dieu, 69007 Lyon, France.
| | | | | | | | | | | |
Collapse
|
38
|
Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Pérault-Pochat MC, Lafay-Chebassier C. Imipramine, in Part through Tumor Necrosis Factor α Inhibition, Prevents Cognitive Decline and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease. J Pharmacol Exp Ther 2009; 332:505-14. [DOI: 10.1124/jpet.109.162164] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
39
|
Johnston D, Juette A, Shaw M, Pain S, Malcolm P. Comparison of ultrasound localisation techniques for impalpable breast cancer. Breast Cancer Res 2009. [PMCID: PMC4284843 DOI: 10.1186/bcr2382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
40
|
Deguil J, Chavant F, Lafay-Chebassier C, Pérault-Pochat MC, Fauconneau B, Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Res 2009; 17:142-55. [PMID: 19626386 DOI: 10.1007/s12640-009-9091-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2008] [Revised: 05/29/2009] [Accepted: 07/08/2009] [Indexed: 02/01/2023]
Abstract
Parkinson's disease (PD) is characterized by a triade of motor symptoms due to the degeneration of nigrostriatal pathway. In addition to these motor impairments, cognitive disturbances have been reported to occur in PD patients in the early stage of the disease. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin widely used to produce experimental models of PD. In a previous work, we showed that MPTP altered the expression of proteins involved in mTOR antiapoptotic and PKR apoptotic pathways of translational control (TC) in neuroblastoma cells. In the present study, the results indicated that a subchronic MPTP intoxication in mice decreased the dopaminergic neuron number, produced an activation of PKR way and an inhibition of mTOR way of TC especially in striatum and frontal cortex associated with a great activation of PKR in hippocampus. Moreover, in parallel to biochemical analysis, the mnesic disturbances induced by MPTP were characterized in C57Bl/6 mice, by testing their performance in three versions of the Morris Water Maze task. Behavioral results showed that the MPTP lesion altered mice learning of a spatial working memory, of a cued version and of a spatial reference memory task in the water maze. Furthermore, we previously demonstrated that the neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) could counteract the MPTP toxicity on TC factors in neuroblastoma cells. Thus, the second objective of our study was to assess the PACAP effect on MPTP-induced TC impairment and cognitive deficit in mice. The pretreatment with PACAP27 by intravenous injections partially protected TH-positive neuron loss induced by MPTP, prevented the MPTP-induced protein synthesis control dysregulation and mnesic impairment of mice. Therefore, our results could indicate that PACAP may be a promising therapeutic agent in Parkinson's disease.
Collapse
Affiliation(s)
- Julie Deguil
- Research Group on Brain Aging, GReViC, EA 3808, Pôle de Biologie Santé, University of Poitiers, Poitiers cedex, France
| | | | | | | | | | | |
Collapse
|
41
|
Deguil J, Perault-Pochat MC, Chavant F, Lafay-Chebassier C, Fauconneau B, Pain S. Activation of the protein p7OS6K via ERK phosphorylation by cholinergic muscarinic receptors stimulation in human neuroblastoma cells and in mice brain. Toxicol Lett 2008; 182:91-6. [PMID: 18809477 DOI: 10.1016/j.toxlet.2008.08.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2008] [Revised: 08/14/2008] [Accepted: 08/26/2008] [Indexed: 11/24/2022]
Abstract
Stimulation of cholinergic muscarinic receptors has been shown to provide substantial protection from DNA damage, oxidative stress and mitochondrial impairment, insults that may be encountered by neurons in development, aging, or neurodegenerative diseases. A study recently indicated that the activation of muscarinic receptors in astrocytoma cells modified the expression of the kinase p70S6K involved in the translational control. The translational control is in part regulated by a cascade of phosphorylation affecting proteins of the anti-apoptotic way controlled by mTOR (mammalian target of rapamycin) and the pro-apoptotic way controlled by PKR. The aim of our study was to investigate the effect of cholinergic muscarinic stimulation by an agonist oxotremorine on the anti-apoptotic way of translational control, in human neuroblastoma cells and in mice brain. Our results showed that muscarinic receptor activation significantly increased the expression of phosphorylated p70S6K, eIF4E and ERK without modification of mTOR activity in neuroblastoma cells and in cerebral cortex and hippocampus of mice, suggesting a stimulation of protein synthesis. Our findings support the notion that synaptic activity, through activation of neurotransmitter receptors, can provide substantial support of cellular survival mechanisms and suggest that loss of such synaptic input increases vulnerability to insult-induced programmed cell death.
Collapse
Affiliation(s)
- Julie Deguil
- University of Poitiers, Research Group on Brain Aging (EA 3808), Pôle de Biologie Santé, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
42
|
Vantelon N, Rioux-Bilan A, Ingrand S, Pain S, Page G, Guillard O, Barrier L, Piriou A, Fauconneau B. Regulation of initiation factors controlling protein synthesis on cultured astrocytes in lactic acid-induced stress. Eur J Neurosci 2007; 26:689-700. [PMID: 17686044 DOI: 10.1111/j.1460-9568.2007.05698.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The goals of this work were first to assess whether the lactic acidosis observed in vivo in ischemia may by itself explain the inhibition of protein synthesis described in the literature and second to study the factors controlling the initiation of protein synthesis under lactic acid stress. Primary rat astrocyte cultures exposed to pH 5.25 underwent cell death and a strong inhibition of protein synthesis assessed by [3H]methionine incorporation, which was solely due to acidity of the extracellular medium and was not related to lactate concentrations. This result was associated with a weak phosphorylation of eukaryotic initiation factor (eIF)4E and a rapid phosphorylation of eIF2alpha via the kinases PKR and PKR-like endoplasmic reticulum kinase. The inhibition of PKR by PRI led first to a significant but not complete dephosphorylation of eIF2alpha that probably contributed to maintain the inhibition of the protein synthesis and second to surprising phosphorylations of extracellular signal-regulated protein kinase, p70S6K and eIF4E, suggesting a possible cross-link between the two pathways. Conversely, cell death was weak at pH 5.5. Protein synthesis was decreased to a lesser extent, the phosphorylation of eIF2alpha was limited, extracellular signal-regulated protein kinase 1/2 was activated and its downstream targets, p70S6K and eIF4E, were phosphorylated. However, the strong phosphorylation of eIF4E was not associated with an activation of the eIF4F complex. This last result may explain why protein synthesis was not stimulated at pH 5.5. However, when astrocytes were exposed at pH 6.2, corresponding to the lower pH observed in hyperglycemic ischemia, no modification in protein synthesis was observed. Consequently, lactic acidosis cannot, by itself, provide an explanation for the decrease in protein synthesis previously reported in vivo in ischemia.
Collapse
Affiliation(s)
- Nadine Vantelon
- Research Group on Brain Aging, University of Poitiers, Pôle de Biologie Santé, EA 3808, 40 avenue du Recteur Pineau, and Department of Clinical Pharmacology, University Hospital, Poitiers, France
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Deguil J, Jailloux D, Page G, Fauconneau B, Houeto JL, Philippe M, Muller JM, Pain S. Neuroprotective effects of pituitary adenylate cyclase–activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells. J Neurosci Res 2007; 85:2017-25. [PMID: 17492795 DOI: 10.1002/jnr.21318] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
UNLABELLED Parkinson's disease (PD) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity are both associated with dopaminergic neuron death in the substantia nigra. Although a variety of evidence has shown that degenerative cells have apoptotic features, the role of apoptosis in disease pathology remains controversial. The 1-methyl-4-phenylpyridinium ion (MPP(+)), a metabolite of MPTP, was recently shown to alter the expression of proteins involved in translational control. The initiation step of translational control is regulated by a cascade of phosphorylation affecting proteins of the antiapoptotic way controlled by mammalian target of rapamycin (mTOR) and of the proapoptotic way controlled by double-stranded RNA protein-dependent kinase (PKR). A study showed that MPP(+) induced an increase in eIF2alpha phosphorylation, leading to inhibition of protein synthesis. THE AIMS OF OUR STUDY WERE (1) to assess the effects of MPP(+) toxicity on molecular factors of PKR and mTOR signaling pathways in murine neuroblastoma cells, and (2) to examine the ability of VIP and PACAP peptides to counteract the MPP(+) toxicity. Our findings showed that MPP(+) induced phosphorylation of eIF2alpha and significantly reduced the expression of phosphorylated mTOR, p70S6K, eIF4E, and 4E-BP1, suggesting its toxicity in controlling protein synthesis. Furthermore, the VIP peptide had no effect on either the PKR or the mTOR signaling pathway. On the contrary, the PACAP 27 neuropeptide prevented MPP(+)-induced eIF2alpha phosphorylation and blocked MPP(+) toxicity in molecular factors of the mTOR pathway. And last, PACAP 27 seemed to protect Neuro-2a cells from the apoptotic process as assessed by the decreased nuclear condensation after DAPI staining. These results could open new paths of research of PACAP in PD.
Collapse
Affiliation(s)
- Julie Deguil
- Groupe de Recherche sur le Vieillissement Cérébral GReViC, Pôle de Biologie Santé, Poitiers, France
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Lafay-Chebassier C, Pérault-Pochat MC, Page G, Rioux Bilan A, Damjanac M, Pain S, Houeto JL, Gil R, Hugon J. The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res 2007; 84:1323-34. [PMID: 16955484 DOI: 10.1002/jnr.21039] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system characterized by two major lesions: extracellular senile plaques and intraneuronal neurofibrillary tangles. beta-Amyloid (Abeta) is known to play a major role in the pathogenesis of AD. Protein synthesis and especially translation initiation are modulated by different factors, including the PKR/eIF2 and the mTOR/p70S6K pathways. mRNA translation is altered in the brain of AD patients. Very little is known about the translation control mediated by mTOR in AD, although mTOR is a central regulator of translation initiation and also ribosome biogenesis and cell growth and proliferation. In this study, by using Western blotting, we show that mTOR pathway is down-regulated by Abeta treatment in human neuroblastoma cells, and the underlying mechanism explaining a transient activation of p70S6K is linked to cross-talk between mTOR and ERK1/2 at this kinase level. This phenomenon is associated with caspase-3 activation, and inhibition of mTOR by the inhibitor rapamycin enhances Abeta-induced cell death. Moreover, in our cell model, insulin-like growth factor-1 is able to increase markedly the p70S6K phosphorylation controlled by mTOR and reduces the caspase-3 activity, but its protective effect on Abeta cell death is mediated via an mTOR-independent pathway. These results demonstrate that mTOR plays an important role as a cellular survival pathway in Abeta toxicity and could represent a possible target for modulating Abeta toxicity.
Collapse
|
45
|
Page G, Rioux Bilan A, Ingrand S, Lafay-Chebassier C, Pain S, Perault Pochat MC, Bouras C, Bayer T, Hugon J. Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience 2006; 139:1343-54. [PMID: 16581193 DOI: 10.1016/j.neuroscience.2006.01.047] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2005] [Revised: 12/28/2005] [Accepted: 01/09/2006] [Indexed: 10/24/2022]
Abstract
Neuronal death is a pathological hallmark of Alzheimer's disease. We have shown previously that phosphorylated double-stranded RNA-dependent protein kinase is present in degenerating hippocampal neurons and in senile plaques of Alzheimer's disease brains and that genetically down-regulating double-stranded RNA-dependent protein kinase activity protects against in vitro beta-amyloid peptide neurotoxicity. In this report, we showed that two double-stranded RNA-dependent protein kinase blockers attenuate, in human neuroblastoma cells, beta-amyloid peptide toxicity evaluated by caspase 3 assessment. In addition, we have used the newly engineered APP(SL)/presenilin 1 knock-in transgenic mice, which display a severe neuronal loss in hippocampal regions, to analyze the activation of double-stranded RNA-dependent protein kinase. Western blots revealed the increased levels of activated double-stranded RNA-dependent protein kinase and the inhibition of eukaryotic initiation factor 2 alpha activity in the brains of these double transgenic mice. Phosphorylated RNA-dependent protein kinase-like endoplasmic reticulum-resident kinase was also increased in the brains of these mice. The levels of activated double-stranded RNA-dependent protein kinase were also increased in the brains of patients with Alzheimer's disease. At 3, 6 and 12 months, hippocampal neurons display double stranded RNA-dependent protein kinase labelings in both the nucleus and the cytoplasm. Confocal microscopy showed that almost constantly activated double-stranded RNA-dependent protein kinase co-localized with DNA strand breaks in apoptotic nuclei of CA1 hippocampal neurons. Taken together these results demonstrate that double-stranded RNA-dependent protein kinase is associated with neurodegeneration in APP(SL)/presenilin 1 knock-in mice and could represent a new therapeutic target for neuroprotection.
Collapse
Affiliation(s)
- G Page
- Research Group on Brain Aging (EA 3808), University of Poitiers, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Page G, Khidir FAL, Pain S, Barrier L, Fauconneau B, Guillard O, Piriou A, Hugon J. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes. Neurochem Int 2006; 49:413-21. [PMID: 16549223 DOI: 10.1016/j.neuint.2006.01.020] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2005] [Revised: 01/18/2006] [Accepted: 01/19/2006] [Indexed: 10/24/2022]
Abstract
Group I metabotropic glutamate receptors (mGluRs) have been demonstrated to play a role in synaptic plasticity via a rapamycin-sensitive mRNA translation signaling pathway. Various growth factors can stimulate this pathway, leading to the phosphorylation and activation of mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that modulates the activity of several translation regulatory factors, such as p70S6 kinase. However, little is known about the cellular and molecular mechanisms that bring the plastic changes of synaptic transmission after stimulation of group I mGluRs. Here, we investigated the role of the mTOR-p70S6K and the ERK1/2-p70S6K pathways in rat striatal and hippocampal synaptoneurosomes after group I mGluR stimulation. Our findings show that (S)-3,5-dihydroxyphenylglycine (DHPG) increases significantly the activation of mTOR and p70S6K (Thr389, controlled by mTOR) in both brain areas. The mTOR activation is dose-dependent and requires the stimulation of mGluR1 subtype receptors as for the p70S6K activation observed in striatum and hippocampus. In addition, the p70S6K (Thr421/Ser424) activation via the ERK1/2 activation is increased and involved also mGluR1 receptors. These results demonstrate that group I mGluRs are coupled to mTOR-p70S6K and ERK1/2-p70S6K pathways in striatal and hippocampal synaptoneurosomes. The translational factor p70S6K could be involved in the group I mGluRs-modulated synaptic efficacy.
Collapse
Affiliation(s)
- Guylène Page
- Research Group on Brain Aging (EA 3808), University of Poitiers, Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Damjanac M, Page G, Rioux-Bilan A, Pain S, Latta-Mahieu M, Pradier L, Hugon J. P1-1 Rôle des voies du contrôle traductionnel PKR et mTOR dans le modèle de souris transgéniques Alzheimer APPSL/PS1 Knock-in. Rev Neurol (Paris) 2005. [DOI: 10.1016/s0035-3787(05)85317-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Pain S, Pussinen P, Sinisalo J, Manila K, Ahlberg J, Valtonen V, Nieminen M, Asikainen S. W01-P-011 Serum LPS and antibodies to periodontal bacteria associate with recurrent cardiovascular events. ATHEROSCLEROSIS SUPP 2005. [DOI: 10.1016/s1567-5688(05)80016-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
49
|
Pain S, Peters A, Barber R, Ballinger J, Solanki C, Mortimer P, Purushotham A. Lymphatico-venous communications protect against development of breast cancer-related lymphoedema. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90918-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
Pain S, Bainbridge C, Purushotham A. Changes to the axillary vein are associated with an increased risk of breast cancer-related lymphoedema. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90909-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|